Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: Results from the Orencia and Rheumatoid Arthritis (ORA) registry

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1108-1113

  Salmon, J H ^a   Gottenberg, J E ^b   Ravaud, P ^c   Cantagrel, A ^d   Combe, B ^e   Flipo, R M ^f   Schaeverbeke, T ^g   Houvenagel, E ^h   Gaudin, P ⁱ   Loeuille, D ^j   Rist, S ^k   Dougados, M ^l   Sibilia, J ^b   Le Loet X ^m   Meyer, O ⁿ   Solau Gervais, E ^o   Marcelli, C ^p   Bardin, T ^q   Pane, I ^c   Baron, G ^c   Perrodeau, E ^c   Mariette, X ^r   more..

^a REIMS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e LAPEYRONIE HOSPITAL   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h CH Lomme   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

^k CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m ROUEN UNIVERSITY HOSPITAL   (France)

ⁿ BICHAT HOSPITAL   (France)

^o POITIERS UNIVERSITY HOSPITAL   (France)

^p CAEN UNIVERSITY HOSPITAL   (France)

^q HÔPITAL LARIBOISIÈRE   (France)

^r UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACICLOVIR; ANTIBIOTIC AGENT; CORTICOSTEROID; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BONE INFECTION; CATHETER INFECTION; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; INFECTION; INFECTION RISK; INFECTIOUS ARTHRITIS; KERATITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PERICARDITIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RISK FACTOR; SEPTICEMIA; SKIN DISEASE; SOFT TISSUE INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION; VIRUS HEPATITIS; AGE; AGED; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CLINICAL TRIAL; FRANCE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MULTICENTER STUDY; OPPORTUNISTIC INFECTIONS; REGISTER;

ABATACEPT; ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; FEMALE; FRANCE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; REGISTRIES; RISK FACTORS;

EID: 84931330480     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207362     Document Type: Article

References (22)

1. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009;82:25-32.
2. Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011;50:222-9.
3. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62:2458-66.
4. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32.
5. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23.
6. Austin PC, Tu JV. Bootstrap methods for developing predictive models. Am Stat 2004;58:131-7.
7. R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013. http://www.R-project.org/
8. Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012;71:374-7.
9. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
10. Gawert L, Hierse F, Zink A, et al. How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. Rheumatology (Oxford) 2011;50:152-60.
11. Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007;46:1345-54.
12. Finckh A, Iannone F, Florenzo GR, et al. The impact of inadequate response to prior biologic agents on abatacept drug retention in rheumatoid arthritis patients. A Pan-European analysis of RA registries [abstract]. Arthritis Rheum 2013;65(Suppl 10):495.
13. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904.
14. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) 2011;50:437-49.
15. Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013;52:986-97.
16. Bigbee CL, Gonchoroff DG, Vratsanos G, et al. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 2007;56:2557-65.
17. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
18. Kubandova Z, Mathieu S, Pourtier C, et al. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody. Joint Bone Spine 2010;77:623-4.
19. Van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-502.
20. Halleux D, Kanaan N, Kabamba B, et al. Hepatitis E virus: an underdiagnosed cause of chronic hepatitis in renal transplant recipients. Transpl Infect Dis 2012;14:99-102.
21. Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2014;73:1673-6.
22. Genovese MC, Breedveld FC, Emery P, et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:1894-7.